ESSA Pharma (NASDAQ:EPIX – Get Rating) and Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.
Analyst Ratings
This is a summary of recent ratings for ESSA Pharma and Alnylam Pharmaceuticals, as provided by MarketBeat.com.
Get ESSA Pharma alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ESSA Pharma | 0 | 0 | 0 | 0 | N/A |
| Alnylam Pharmaceuticals | 0 | 5 | 12 | 0 | 2.71 |
ESSA Pharma presently has a consensus price target of $20.00, indicating a potential upside of 998.90%. Alnylam Pharmaceuticals has a consensus price target of $232.06, indicating a potential upside of 12.44%. Given ESSA Pharma's higher probable upside, research analysts clearly believe ESSA Pharma is more favorable than Alnylam Pharmaceuticals.
Volatility & Risk
ESSA Pharma has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.Profitability
This table compares ESSA Pharma and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ESSA Pharma | N/A | -20.39% | -19.95% |
| Alnylam Pharmaceuticals | -110.91% | -204.18% | -28.26% |
Earnings & Valuation
This table compares ESSA Pharma and Alnylam Pharmaceuticals' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ESSA Pharma | N/A | N/A | -$36.81 million | ($0.86) | -2.12 |
| Alnylam Pharmaceuticals | $844.29 million | 29.34 | -$852.82 million | ($8.17) | -25.26 |
ESSA Pharma has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
93.2% of Alnylam Pharmaceuticals shares are held by institutional investors. 9.9% of ESSA Pharma shares are held by insiders. Comparatively, 1.4% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ESSA Pharma beats Alnylam Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About ESSA Pharma
(Get Rating)
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
About Alnylam Pharmaceuticals
(Get Rating)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.